Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
May 2020
Historique:
received: 22 10 2019
accepted: 17 12 2019
pubmed: 4 1 2020
medline: 15 12 2020
entrez: 4 1 2020
Statut: ppublish

Résumé

The purpose of this study is to assess risk factors for the acquisition of extended-spectrum β-lactamase-producing Gram-negative bacilli (ESBL-GNB) colonization and infection (AI) in ICUs with low ESBL-GNB prevalence rate. We conducted a retrospective observational study in three ICUs in Bretagne, France. All patients admitted from January 2016 to September 2017 with a length of stay of 2 days or more were included. Universal screening for ESBL-GNB colonization was performed in all participating ICUs. Of the 3250 included patients, 131 (4.0%) were colonized at admission, 59 acquired colonization while hospitalized (1.9%; 95% CI [1.5-2.5%]), and 15 (0.5%; 95% CI [0.3-0.8%]) acquired ESBL-GNB infections. In the case of infection, the specificity and the negative predictive values of preexistent colonization for the ESBL-GNB etiology were 93.2% [91.5-95.1%] and 95.2% [93.5-97.1%], respectively. Colonization was the main risk factor for ESBL-GNB AI (OR = 9.61; 95% CI [2.86-32.29]; p < 0.001). Antimicrobial susceptibility of non-ESBL-GNB isolates responsible for AI was similar for any non-carbapenem β-lactam (95%) and imipenem (94%). ESBL-GNB AIs were rare in ICUs with low ESBL-GNB prevalence rate. Prior colonization was the main risk factor for subsequent infection. Empirical carbapenem therapy could be avoided in non ESBL-GNB colonized patients with suspected AI.

Identifiants

pubmed: 31898797
doi: 10.1007/s10096-019-03800-y
pii: 10.1007/s10096-019-03800-y
pmc: PMC7222057
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0
beta-Lactamases EC 3.5.2.6

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

889-895

Références

Medicine (Baltimore). 2014 Oct;93(17):298-309
pubmed: 25398065
Crit Care Med. 2014 May;42(5):1121-30
pubmed: 24365857
Lancet Infect Dis. 2013 Aug;13(8):665-71
pubmed: 23622939
Microb Drug Resist. 2006 Spring;12(1):50-8
pubmed: 16584309
J Infect. 2016 Sep;73(3):200-9
pubmed: 27373765
PLoS One. 2018 Aug 8;13(8):e0201688
pubmed: 30089150
Antimicrob Agents Chemother. 2006 Feb;50(2):498-504
pubmed: 16436702
Crit Care Med. 2016 Apr;44(4):699-706
pubmed: 26571186
Clin Microbiol Rev. 2001 Oct;14(4):933-51, table of contents
pubmed: 11585791
Intensive Care Med. 2018 May;44(5):616-626
pubmed: 29663045
Clin Infect Dis. 2012 Dec;55(11):1505-11
pubmed: 22955436
Ann Intensive Care. 2017 Dec;7(1):61
pubmed: 28608133
Crit Care Med. 2017 Apr;45(4):705-714
pubmed: 28157141
J Hosp Infect. 2013 Aug;84(4):294-9
pubmed: 23846237
Eur Respir J. 2017 Sep 10;50(3):
pubmed: 28890434
J Antimicrob Chemother. 2016 Apr;71(4):1088-97
pubmed: 26755492
Crit Care. 2011;15(2):R100
pubmed: 21418635
Am J Infect Control. 2012 Nov;40(9):845-8
pubmed: 22325483
Infect Control Hosp Epidemiol. 2005 Feb;26(2):161-5
pubmed: 15756887
Clin Infect Dis. 2007 Nov 15;45(10):1347-50
pubmed: 17968833
Antimicrob Resist Infect Control. 2019 Jul 10;8:112
pubmed: 31333839
Am J Infect Control. 1988 Jun;16(3):128-40
pubmed: 2841893
Clin Infect Dis. 2018 Feb 1;66(4):497-503
pubmed: 29186403
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Clin Microbiol Infect. 2020 Apr;26(4):485-491
pubmed: 31421272
Am J Infect Control. 2012 Jun;40(5):396-407
pubmed: 21908073
Intensive Care Med. 2012 Dec;38(12):1930-45
pubmed: 23011531
Clin Microbiol Infect. 2018 Apr;24(4):429.e7-429.e12
pubmed: 28962997

Auteurs

Nicolas Massart (N)

Service de Maladie Infectieuse et de Réanimation Médicale CHU de Rennes, 2, rue Henri le Guilloux, 35000, Rennes, France. nicolasmassart@hotmail.fr.
Faculté de Médecine, Biosit, Université Rennes 1, F-35043, Rennes, France. nicolasmassart@hotmail.fr.

Christophe Camus (C)

Service de Maladie Infectieuse et de Réanimation Médicale CHU de Rennes, 2, rue Henri le Guilloux, 35000, Rennes, France.
Faculté de Médecine, Biosit, Université Rennes 1, F-35043, Rennes, France.
Inserm-CIC-1414, Faculté de Médecine, Université Rennes I, IFR 140, F-35033, Rennes, France.

François Benezit (F)

Service de Maladie Infectieuse et de Réanimation Médicale CHU de Rennes, 2, rue Henri le Guilloux, 35000, Rennes, France.
Faculté de Médecine, Biosit, Université Rennes 1, F-35043, Rennes, France.
Inserm-CIC-1414, Faculté de Médecine, Université Rennes I, IFR 140, F-35033, Rennes, France.

Mikael Moriconi (M)

Service de Réanimation, CH de Quimper, 14bis Avenue Yves Thépot, 29107, Quimper, France.

Pierre Fillatre (P)

Service de Réanimation, CH de St Brieuc, 10, rue Henry le Guilloux, 22000, Saint-Brieuc, France.

Yves Le Tulzo (Y)

Service de Maladie Infectieuse et de Réanimation Médicale CHU de Rennes, 2, rue Henri le Guilloux, 35000, Rennes, France.
Faculté de Médecine, Biosit, Université Rennes 1, F-35043, Rennes, France.
Inserm-CIC-1414, Faculté de Médecine, Université Rennes I, IFR 140, F-35033, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH